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A B S T R A C T
Our aim was to quantify circulating B cell subsets; immature/transitional, naïve, CD27− and CD27+ memory
cells and plasmablasts, in relapsing-remitting multiple sclerosis patients treated with IFN-β. The most relevant
findings were a significant increase of plasmablasts and a decrease of immature/transitional B cells, resulting in
a decreased ratio between those cells in relapse RRMS, together with an increase of CD27− and CD27+IgM+
memory B cell subsets in both phases of the disease. These alterations point to an active B cell response, par-
ticularly in relapse, and the above referred ratio could constitute a good biomarker of relapse in patients that
underwent IFN-β treatment.
1. Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central
nervous system (CNS). The pathology of MS leads to demyelination,
astrocytic and neuronal injury (Wilson, 2012). The pathogenesis is still
incompletely understood, and the cause remains unknown (Bittner
et al., 2017).
MS has long been considered a ‘classical’ T-cell-mediated auto-
immune disorder. However, the involvement of the humoral immunity
has always been present by intrathecal synthesis of oligoclonal bands
(OCB) in the cerebrospinal fluid (CSF), but not in serum, of about 90%
of relapsing-remitting (RR)MS patients (Bittner et al., 2017; Sospedra,
2018). Despite years of research, the antigen-specificity of autoreactive
antibodies in MS is still not clear (Staun-Ram and Miller, 2017). OCB
are the most consistent immunodiagnostic feature and hallmark im-
munologic finding in MS. The accumulating evidence has brought B
cells into focus as critical players in MS pathogenesis (Disanto et al.,
2012).
B cells may be observed in the healthy brain but are scarce in
number and increase drastically during neuroinflammation (Blauth
et al., 2015). B cells may contribute to MS pathogenesis as precursors of
antibody (Ab) secreting plasma cells, as antigen presenting cells for
activation of T cells, and as producers of cytokines with pro- or anti-
inflammatory properties (Lehmann-Horn et al., 2013). Because of OCB,
their pathogenic function has been traditionally associated with Ab
production.
According to phenotypic profile of B cell subsets, which also reflects
their functional abilities and behavior, four major maturation-asso-
ciated subsets can be identified in the human peripheral blood (PB):
immature/transitional, naïve, memory and plasmablast (Perez-Andres
et al., 2010). In the germinal center (GC), B cells gain CD27, a marker
considered as a hallmark of memory B cells, and whose expression
correlates with the presence of somatic mutations in immunoglobulins
genes (Fecteau and Ne, 2008; Berkowska et al., 2011; García-Sanz et al.,
2016). In MS memory B cells, plasmablasts, and plasma cells pre-
ferentially cross the disrupted blood brain barrier (BBB) and migrate
into the CNS, where they dominate the B cell pool and exert different
effector functions (Claes et al., 2015; Sospedra, 2018).
More than two decades have passed since interferon-β (IFN-β) was
established as the first disease-modifying therapy (DMT) found to be
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effective in the management of MS. It remains a valid approach because
of its good benefit/risk profile (Rizo et al., 2016).
Recently, the introduction of B-cell-depleting therapies, which rapidly
reduce B cells and eliminate their pathogenicity in MS, demonstrates a
strong efficacy in RRMS, despite their inability to deplete CD20 negative
circulating plasma cells. However, treated patients seemed to have stable
plasma cell numbers and unchanged OCB production in the CSF. This im-
plies that the most critical role of B cells in MS disease development could
be not linked to their Ab-producing capacity, but to their role in antigen
presentation and regulation of T cell differentiation and effector functions in
the development of the autoimmune response (Ramgolam et al., 2011;
Michel et al., 2015; Bittner et al., 2017; Li et al., 2018).
There are still many unresolved questions surrounding MS and the B
cells in this disease. Possibly, B cells have been underestimated in the
immunopathogenesis of MS. In this scenario, the aim of this work was
to characterize circulating B cell subsets in remission and relapse RRMS
patients treated with IFN-β and compare to healthy controls.
2. Material and methods
2.1. Patients and healthy controls
This study enrolled 38 patients with the diagnosis of RRMS based on
clinical, magnetic resonance image, and biochemical principles, ac-
cording to the MacDonald criteria 2010 (Polman et al., 2011). The in-
clusion condition was the treatment with IFN-β. The exclusion criteria
were the corticosteroid treatment, active infection, local or systemic
disease affecting the immune system (neoplasia, psoriasis, chronic in-
flammatory, or other autoimmune diseases), pregnancy, and other
treatments for MS. A relapse was defined as an acute inflammatory
demyelinating event in the CNS with a duration of at least 24 h, in the
absence of fever or infection, and documented with neurological find-
ings. Disability was scored on the Expanded Disability Status Scale
(EDSS), ranging from 0 to 10, with higher scores indicating greater
disability. Patients were divided into two groups according to the phase
of the disease. 30 patients in remission and 8 patients in relapse.
The group of healthy controls (HC) were composed by 20 healthy
age- and gender-matched volunteers. The inclusion criteria for this
group were the absence of autoimmune diseases and/or active infection
and no treatment with immunomodulatory drugs. The complete de-
mographic and clinical characteristics of patients and HC involved can
be found in Table 1.
All patients and volunteers signed an informed consent and the
study was approved by the ethics committee of Centro Hospitalar Cova
da Beira with number 54.
2.2. Immunofluorescence staining of peripheral B cell subsets
For the identification of B cell subsets, the following monoclonal
antibodies were added to 250 μl of PB collected in K3-EDTA: CD20-PB
(Pacific Blue; clone 2H7; BioLegend, San Diego, CA, USA); CD27-PC5
(phycoerythrin-cyanine 5; clone 1A4LDG5; Beckman Coulter; USA);
CD19-PC7 (phycoerythrin-cyanine 7; clone J3–119; Beckman Coulter,
France); CD45-KO (Krome Orange; clone J.33; Beckman Coulter,
France); CD38-APC-H7 (allophycocyanin-hilite7; clone HB7; BD
Biosciences, San Jose, CA, USA). The samples were then incubated for
15min at room temperature and kept in the dark. To determine the
immunoglobulin class, an intracytoplasmic staining was performed
with the monoclonal antibodies IgG-FITC (fluorescein isothiocyanate,
clone G18–145, BD Pharmingen, San Diego, CA, USA), IgA-PE (phy-
coerythrin, clone IS11-8E10, Macs Miltenyi Biotec, Bergisch Gladbach,
Germany) and IgM-APC (allophycocyanin, clone G20–127, BD
Pharmingen) using IntraPrep kit (Beckman Coulter, Brea, CA, USA)
according to the supplier instructions. The cell pellet was resuspended
in 0.5 ml of phosphate buffer saline (Gibco, Paisley, Scotland). The flow
cytometry gating strategy to identify circulating B cell subsets is shown
in Fig. 1.
2.3. Flow cytometry data acquisition and analysis
Data acquisition was performed in FACSCanto™II (BD) flow cyt-
ometer equipped with FACSDiva software (version 6.1.2: BD). The
number of events acquired was always above 0.5×106. For data
analysis, Infinicyt (version 1.8) software (Cytognos SL, Salamanca,
Spain) was used.
2.4. Statistical analysis
The statistical evaluation of the obtained results was done using the
non-parametric Mann-Whitney U test. The results were expressed as the
median ± standard deviation (SD). All statistical analyses were per-
formed using SPSS software program (version 23.0) (IBM, Amonk, NY,
USA). p values< .05 were considered statistically significant.
Table 1







Age (median ± SD) 48 ± 9 44 ± 11 41 ± 10
Male (%) 20% 10% 37.5%
Female (%) 80% 90% 62.5%
Leukocytes (median ± SD x109/l) 7.1 ± 2.0 6.6 ± 2.0 8.4 ± 4.9
EDSS-score (median ± SD) NA 1.8 ± 1.1 3 ± 2.1
Age disease of the onset (median ± SD) NA 32.7 ± 9.9 34.9 ± 10.3
Disease duration (median ± SD, years) NA 11.1 ± 8.2 4.8 ± 5.7
Treatment
IFN-beta 1a SI 22 μg 3× week (n) NA 1 0
Length of treatment (median ± SD, years) NA 2 0
IFN-beta 1a SI 44 μg 3× week (n) NA 3 1
Length of treatment (median ± SD, years) NA 5.7 ± 4.0 3
IFN-beta 1a IM 30 μg 1× week(n) NA 14 3
Length of treatment (median ± SD, years) NA 6.4 ± 2.3 9.0 ± 4.2
IFN-beta 1b IM 250 μg every other day (n) NA 10 4
Length of treatment (median ± SD, years) NA 4.8 ± 2.2 5.7 ± 1.2
IFN-beta 1b IM 250 μg every other day (n) NA 2 0
Length of treatment (median ± SD, years) NA 4.0 ± 1.4 0
Untreated patients NA 0 0
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3. Results and discussion
The participation of B cells in MS has always been supported by the
presence of OCB in the CSF. Because of the good results of new ther-
apeutics directed to B cells, the study of these lymphocytes is becoming
a hot point in MS research.
IFN-β and glatiramer acetate (GA) are the first line of DMT for
RRMS. How GA therapy directly affects B cells in MS patients is still not
conclusive, and most of the information comes from the experimental
autoimmune encephalomyelitis model (Ireland et al., 2014). Therefore,
the literature is not unanimous about the effect of GA therapy on B cells
from RRMS patients. In vitro studies refer that changes in B cells in IFN-
Fig. 1. Flow cytometry strategy to identify circulating B cell subsets: immature/transitional, naïve, memory and plasmablasts, and the expression of IgM, IgG and IgA
in CD27+ and CD27− memory B cell subsets and plasmablast.
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β treated patients is directly due to IFN-β treatment and not a general
feature of MS disease in remission (Schubert et al. 2015). At this time, it
will be impossible for us to add a new cohort of patients undergoing a
different therapy. Although, a very preliminary data from our group in
MS patients treated with Rituximab, an increase in plasmablasts fre-
quency seemed to be associated to a worse response to therapy.
All the patients included were responders to the IFN-β therapy,
since the minimum of the length treatment was two years. (Table 1) The
formulations of IFN-β were different, however in the literature there are
no differences between the effect of IFN-β formulations on B cell subsets
(Staun-Ram and Miller, 2017; Li et al., 2018; Sospedra, 2018).
In the periphery, based on surface markers, we identified the following B
cell subsets: immature/transitional CD19+CD20+CD27−CD45+CD38++;
naïve CD19+CD20+CD27−CD45+CD38−; CD27+ memory CD19+CD20+
CD27+CD45+CD38+low; CD27− memory CD19+CD20+CD27−CD45+
CD38+low; plasmablast CD19+lowCD20−CD27++CD45+CD38+high (García-
Sanz et al., 2016; Blanco et al., 2018) (Table 2, Fig. 1). The circulation of
these cells makes PB an accessible biological sample that mirrors the immune
status and provides a ‘window’ into the immunopathogenesis of MS.
3.1. Frequency of immature/transitional B cell subset and plasmablasts
In remission RRMS patients the percentage of immature/transitional
B cells increases (Table 2, Fig. 2). In accordance to previous reports,
IFN-β treatment increases immature/transitional B cell subset and a
higher proportion of newly released B cells was found (Longbrake and
Cross, 2016). This subset is able to secrete high levels of anti-in-
flammatory and immunomodulatory cytokine IL-10 (Staun-Ram and
Miller, 2017), acting as regulatory B-cells (Perez-Andres et al., 2010). In
systemic lupus erythematosus, immature/transitional B cells emerge as
promising surrogate markers for disease activity (Henriques et al.,
2016). In RRMS, the increase of immature/transitional B cell subset can
be seen as an attempt to increase anti-inflammatory cytokines.
IFN-β can also promote the induction of the expression of B-cell
survival factor and B-cell–activating factor of the tumor necrosis factor
family (BAFF). BAFF promotes the survival of B cells at and beyond the
immature/transitional stage of development. Meanwhile, there was a
decrease in the proportion of circulating class-switched memory B cells
(Schubert et al. 2015; Longbrake and Cross, 2016).
The relapsing RRMS patients exhibited the main changes in B cell
subsets homeostasis, resulting in a decrease in the total population of B
cells, including a decrease of the immature/transitional and naïve B cell
subsets when compared with remission RRMS patients. On the other
hand, the plasmablast B cell subset presented an increase in relapse
RRMS patients (Table 2, Fig. 2). In fact, we calculated the ratio between
immature/transitional B cells and plasmablasts and observed a statis-
tically significant decrease in relapse when compared to remission
RRMS (Fig. 2). Moreover, we compared the results for these two B cell
subsets in four patients at both disease phases and in all of them we
observed a decreased frequency of immature/transitional B cells and an
increased frequency of plasmablasts in relapse (Fig. 3 A,B,C).
Despite the CNS has been traditionally considered immunologically
privileged there are growing evidences suggesting that B cells are able
to travel back and forth across the BBB and commonly reenter GC (in
the meninges or cervical lymph nodes) to undergo further somatic
hypermutations (Bittner et al., 2017; Li et al., 2018). A bidirectional
exchange across the BBB was supported by recent somatic hypermu-
tation studies indicating that B cells identify their specific antigen in the
CNS and can undergo affinity maturation (Staun-Ram and Miller, 2017;
Eggers et al., 2017). These new and recent data may lead us to suppose
Table 2
Frequency and absolute value of B cell subsets in healthy controls and remission and relapse RRMS patients.
HC Remission RRMS Relapse RRMS
% cells/μl % cells/μl % cells/μl
B cell* 3.2 ± 1.6 226.6 ± 119.5 3.7 ± 2.4 238.4 ± 147.1 2.5 ± 1.0b 171.4 ± 57.4b
Immature/transitional 4.3 ± 1.5 9.3 ± 5.0 6.1 ± 4.3a 13.4 ± 12.6 4.7 ± 2.4 8.2 ± 4.2b
Naïve 70.9 ± 14.7 152.8 ± 94.1 65.3 ± 10.2 153.0 ± 115.6 58.5 ± 12.0 93.6 ± 43.2b
Memory 30.6 ± 15.1 71.9 ± 48.9 26.1 ± 10.4 57.9 ± 35.3 33.6 ± 13.0 36.8 ± 26.5
CD27+ Memory 24.6 ± 15.1 60.0 ± 48.9 20.9 ± 9.5 37.6 ± 25.8 26.9 ± 12.5 30.9 ± 24.2
IgA 14.4 ± 4.9 7.0 ± 3.8 17.0 ± 4.3 6.1 ± 3.8 12.9 ± 3.4 4.2 ± 3.2
IgG 44.2 ± 21.3 22.0 ± 16.0 26.3 ± 11.4a 10.3 ± 8.3 30.6 ± 11.7 9.9 ± 12.0
IgM 21.9 ± 16.6 9.1 ± 7.2 44.8 ± 15.4a 19.7 ± 6.0 43.6 ± 11.5a 13.3 ± 10.8
Ig− 10.9 ± 13.2 5.1 ± 7.1 5.1 ± 8.4 1.5 ± 6.0 15.4 ± 6.1 4.4 ± 3.7
CD27− Memory 1.8 ± 0.9 3.3 ± 1.7 3.6 ± 2.2a 7.7 ± 6.2a 4.0 ± 2.3a 6.7 ± 3.8
IgA 61.6 ± 17.7 1.7 ± 1.4 44.5 ± 15.3a 3.3 ± 3.1 41.0 ± 22.5a 2.7 ± 2.3
IgG 38.4 ± 17.8 1.1 ± 0.8 55.5 ± 15.3a 4.1 ± 3.9 59.1 ± 22.5a 3.6 ± 3.3
Plasmablasts 0.5 ± 0.9 1.2 ± 0.9 0.8 ± 0.8 2.4 ± 1.9 2.0 ± 1.3a 1.6 ± 1.7
IgA 32.2 ± 10.3 0.3 ± 0.4 32.8 ± 9.5 0.9 ± 0.6 34.0 ± 13.7 0.7 ± 1.0
IgG 45.3 ± 14.2 0.3 ± 03 37.4 ± 14.5 0.9 ± 1.0 27.9 ± 11.7 0.8 ± 0.5
IgM 16.2 ± 15.0 0.1 ± 0.4 27.0 ± 11.8a 0.4 ± 0.7 25.3 ± 9.6 0.5 ± 0.5
Ig− 7.9 ± 9.8 0.1 ± 0.1 1.8 ± 4.2 0.1 ± 0.1 2.7 ± 3.7 0.1 ± 0.1
Ratio (Immature/Transitional)/
Plasmablasts
9.8 ± 7.4 8.2 ± 13.9 2.7 ± 3.6a,b
Results are expressed as median ± standard deviation. *Number of cells from total peripheral blood lymphocytes; HC, Healthy controls, RRMS, Relapsing-remitting
multiple sclerosis; p value was determined by Mann Whitney U teste; Statistically significant differences (P < 0.05) found between aRemission or Relapse RRMS
patients vs HC, bRemission RRMS patients vs Relapse RRMS patients, marked in bold.
Fig. 2. Frequency of immature, naïve, memory, CD27+ memory, CD27−
memory, plasmablasts B cell subsets and ratio between the (immature/transi-
tional) B cells and plasmablasts, in healthy controls, in remission, and relapse
RRMS patients. * Remission or relapse RRMS patient's vs Healthy controls; **
Remission RRMS patients vs Relapse RRMS patients, with p < .05.
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that the increase of plasmablasts in circulation of relapsing episodes
may also be due to a migration of these cells from cervical lymph nodes
and/or from B cell aggregates described in the meninges of MS patients
to the BM in an attempt to promote the immune response (Mitsdoerffer
and Peters, 2016).
3.2. Memory B cell subsets
The human memory B-cell compartment is more complex than
originally thought based on their antigen-experienced phenotype and
differential expression of CD27 and immunoglobulin heavy chain iso-
types. Though CD27 is a hallmark of memory B cells, CD27− memory B
cells had been identified, namely CD27−IgG+ and CD27−IgA+ class-
switched B cells (Fecteau et al., 2006; Wei et al., 2007; Berkowska et al.,
2011; Centuori et al., 2018).
Concerning memory B cell subsets there is an increase of
CD27+IgM+ and CD27−IgG+ cells, accompanied by a decrease of
CD27−IgA+, in both groups of RRMS patients. Several studies have
already shown an expansion of CD27+IgM+ and CD27−IgG+ memory
B cell subsets in autoimmune diseases (Wei et al., 2007; Perez-Andres
et al., 2010; Berkowska et al., 2011).
In vitro treatment of B cells with IFN-β inhibits B cells' stimulatory
capacity by reducing CD40 and CD80 expression, for both RRMS pa-
tients and healthy controls (Staun-Ram and Miller, 2017). The strength
of CD40 signaling may influence differentiation along the plasma cell
versus GC B-cell pathway. In the absence of CD40, GC formation is
avoided and Ab responses are largely limited to low-affinity IgM
(Rickert et al., 2011). This mechanism could, at least in part, explain
the increase of CD27+IgM+ memory B cells observed in our groups of
patients, since this subset can be generated independently of a func-
tional GC. (García-Sanz et al., 2016).
The CD27− memory B cell subset has undergone class switching,
though they do not gain the expression of CD27. Little is known about
the function of these cells in immunity (Centuori et al., 2018). It is
therefore tempting to postulate that CD27− memory cells develop
outside the GC in extrafollicular reactions. The absence of CD27 might
impair the ability of these cells to receive the full and sustained degree
of T cell help required to complete a GC reaction (Wei et al., 2007).
Based on the new recirculation of B cells through BBB, as already de-
scribed, CD27−IgG+ memory B cell subset may be originated in CNS,
more exactly in the B cell aggregates described in the meninges of MS
patients (Mitsdoerffer and Peters, 2016).
4. Conclusion
In conclusion it was seen that participation of B cells in RRMS goes
far beyond antibody production alone. Recent data from a bidirectional
exchange of B cells through BBB makes the study of B cell subsets even
more relevant to be useful for monitoring the disease activity in RRMS
patients.
In fact, not only RRMS patients exhibited increased frequencies of
CD27+IgM+ and CD27−IgG+ memory B cells, but also relapse patients
had increased levels of plasmablasts that, together with a decrease of
immature/transitional B cells, induce a significant decrease in the ratio
of this two B cell subsets. Thus, this ratio could constitute a good bio-
marker to monitor response to therapy that could be relevant in B cell
depletion in monoclonal antibodies-based therapy.
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